

Friedhelm Raue

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6080501/friedhelm-raue-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

9,112
citations

44
h-index

90
g-index

281
ext. papers

10,237
ext. citations

4.4
avg, IF

5.51
L-index

#	Paper	IF	Citations
218	Medullary thyroid cancer with ectopic Cushing syndrome: A multicentre case series. <i>Clinical Endocrinology</i> , 2021 ,	3.4	1
217	Similar Stage-dependent Survival and Outcome in Sporadic and Hereditary Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3582-e3591	5.6	4
216	Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 1861-1868	5.8	6
215	Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. <i>Thyroid</i> , 2021 , 31, 459-469	6.2	16
214	Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	4
213	Age-Related Association of Calcitonin with Parameters of Anthropometry, Bone and Calcium Metabolism during Childhood. <i>Hormone Research in Paediatrics</i> , 2020 , 93, 361-370	3.3	2
212	Multiple endokrine Neoplasie. <i>Onkologie Up2date</i> , 2020 , 2, 19-29	0	
211	CT- and ultrasound-characteristics of hepatic lesions in patients with multiple endocrine neoplasia syndrome. A retrospective image review of 25 cases. <i>PLoS ONE</i> , 2019 , 14, e0212865	3.7	0
210	Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1242-1250	5.9	7
209	Familie hypocalciurische Hypercalcämie Aktuelle Diagnostik und Therapie 2019. <i>Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen</i> , 2019 , 26, 44-49	0.1	
208	Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4264-4272	5.6	10
207	Medulläres Schilddrüsenkarzinom. <i>Onkologie</i> , 2019 , 25, 573-579	0.1	
206	Primärer Hyperparathyreoidismus Internistische Therapie 2019 , 429-432		
205	Hypoparathyreoidismus 2019 , 433-435		
204	Long-Term Survivorship in Multiple Endocrine Neoplasia Type 2B Diagnosed Before and in the New Millennium. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 235-243	5.6	21
203	Calcitonin Screening in Nodular Goiter-Upper Limits. <i>Deutsches Arzteblatt International</i> , 2018 , 115, 221	2.5	0
202	Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma. <i>Journal of the Endocrine Society</i> , 2018 , 2, 933-943	0.4	25

201 Molecular Genetics of MEN2-Related Neuroendocrine Tumours **2017**, 65-81

200 Pheochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. *Clinical Endocrinology*, **2017**, 87, 320-326 3.4 19

199 Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?. *World Journal of Surgery*, **2017**, 41, 2026-2032 3.3 24

198 A Novel Mutation of the Calcium Sensing Receptor Gene in a Franconian Kindred: Heterozygous Mutation c.1697_1698delTG Exon 6. *Hormone and Metabolic Research*, **2017**, 49, 142-146 3.1 2

197 United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin. *Clinical Chemistry*, **2017**, 63, 1489-1496 5.5 20

196 Long-Term Follow-Up and Treatment of Postoperative Permanent Hypoparathyroidism in Patients with Medullary Thyroid Carcinoma: Differences in Complete and Partial Disease. *Hormone and Metabolic Research*, **2016**, 48, 806-813 3.1 9

195 Molekulargenetische Diagnostik beim medullären Schilddrüsenkarzinom. *Chinese Journal of Polymer Science (English Edition)*, **2016**, 39, 120-123 0.1

194 Heterozygous inactivating CaSR mutations causing neonatal hyperparathyroidism: function, inheritance and phenotype. *European Journal of Endocrinology*, **2016**, 175, 421-31 6.5 26

193 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid*, **2015**, 25, 567-610 6.2 1191

192 Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation. *Recent Results in Cancer Research*, **2015**, 204, 139-56 1.5 39

191 Long-Term Follow-up in Medullary Thyroid Carcinoma. *Recent Results in Cancer Research*, **2015**, 204, 207-25 21

190 Medullary Thyroid Carcinoma: Imaging. *Recent Results in Cancer Research*, **2015**, 204, 91-116 1.5 11

189 Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma. *Recent Results in Cancer Research*, **2015**, 204, 61-90 1.5 28

188 Risk-stratified follow-up of patients with medullary thyroid carcinoma. *International Journal of Endocrine Oncology*, **2015**, 2, 249-252 0.3

187 Management des fortgeschrittenen medullären Schilddrüsenkarzinoms. *Onkologie*, **2014**, 20, 591-598 0.1 0

186 Amino alcohol- (NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome Type 5 and autosomal dominant hypocalcemia. *PLoS ONE*, **2014**, 9, e115178 3.7 21

185 Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. *Thyroid*, **2013**, 23, 294-300 6.2 72

184 Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. *European Journal of Endocrinology*, **2013**, 168, 307-14 6.5 62

183	Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. <i>Clinical Endocrinology</i> , 2012 , 76, 691-7	3-4	25
182	The Calcium-Sensing Receptor: Physiology and Pathophysiology 2012 , 69-90		
181	Clinical utility gene card for: multiple endocrine neoplasia type 2. <i>European Journal of Human Genetics</i> , 2012 , 20,	5-3	4
180	Genotype-phenotype correlation in multiple endocrine neoplasia type 2. <i>Clinics</i> , 2012 , 67 Suppl 1, 69-75	2-3	54
179	Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 2011 , 75, 50-5	3-4	42
178	Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia - a German survey. <i>Clinical Endocrinology</i> , 2011 , 75, 760-5	3-4	65
177	Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels--an observational study during clinical practice conditions. <i>Osteoporosis International</i> , 2011 , 22, 231-40	5-3	19
176	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. <i>Human Mutation</i> , 2011 , 32, 51-8	4-7	98
175	Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. <i>Clinical Chemistry</i> , 2011 , 57, 467-74	5-5	63
174	CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum. <i>European Journal of Endocrinology</i> , 2011 , 165, 477-83	6-5	27
173	Rapid response to sorafenib in metastatic medullary thyroid carcinoma. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011 , 119, 151-5	2-3	15
172	Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. <i>Expert Review of Endocrinology and Metabolism</i> , 2010 , 5, 867-874	4-1	1
171	Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS-2143 mitigates excessive signal transduction of mutant receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, E229-33	5-6	48
170	New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2010 , 118, 550-3	2-3	12
169	Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. <i>Molecular and Cellular Endocrinology</i> , 2010 , 322, 2-7	4-4	85
168	Multiple endocrine neoplasia type 2. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010 , 24, 371-87	6-5	68
167	Update multiple endocrine neoplasia type 2. <i>Familial Cancer</i> , 2010 , 9, 449-57	3	101
166	Primärer Hyperparathyreoidismus 2010 , 289-296		

165 Multiple endokrine Neoplasie **2010**, 475-483

164 Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. *Hormones*, **2009**, 8, 23-8 3.1 61

163 Mutational analysis of the PHEX gene: novel point mutations and detection of large deletions by MLPA in patients with X-linked hypophosphatemic rickets. *Calcified Tissue International*, **2009**, 85, 211-20 3.9 19

162 Multiple endocrine neoplasia type 2 (MEN 2). *European Journal of Cancer*, **2009**, 45 Suppl 1, 267-73 7.5 11

161 Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. *Clinical Endocrinology*, **2008**, 69, 259-63 3.4 48

160 Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. *European Journal of Endocrinology*, **2008**, 158, 811-6 6.5 36

159 Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. *Endocrine-Related Cancer*, **2008**, 15, 1035-41 5.7 39

158 Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 4797-803 5.6 62

157 Multiple endokrine Neoplasie Typ 2 und medulläres Schilddrüsenkarzinom. *Monatsschrift Fur Kinderheilkunde*, **2008**, 156, 981-986 0.2 0

156 Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. *Clinical Endocrinology*, **2007**, 67, 613-22 3.4 74

155 Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. *Experimental and Clinical Endocrinology and Diabetes*, **2007**, 115, 509-17 2.3 41

154 Relapsing pheochromocytoma in a Chinese women caused by a novel mutation in exon 6 of the SDHB gene: a case report. *Experimental and Clinical Endocrinology and Diabetes*, **2007**, 115, 616-8 2.3 2

153 Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. *European Journal of Endocrinology*, **2007**, 157, 215-20 6.5 90

152 Multiple endocrine neoplasia type 2: 2007 update. *Hormone Research in Paediatrics*, **2007**, 68 Suppl 5, 101-4 3.3 31

151 Change in the spectrum of RET mutations diagnosed between 1994 and 2006. *Clinical Laboratory*, **2007**, 53, 273-82 2 24

150 The role of the extracellular calcium-sensing receptor in health and disease. *Experimental and Clinical Endocrinology and Diabetes*, **2006**, 114, 397-405 2.3 28

149 Late diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Experimental and Clinical Endocrinology and Diabetes*, **2006**, 114, 208-14 2.3 3

148 Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. *European Journal of Endocrinology*, **2006**, 155, 229-36 6.5 110

147	Medulläres Schilddrüsenkarzinom 2006 , 4071-4091		2
146	Diagnostik des Schilddrüsenkarzinoms. <i>Onkologe</i> , 2005 , 11, 50-57	0.1	1
145	Coincidence of multiple endocrine neoplasia types 1 and 2: mutations in the RET protooncogene and MEN1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4063-7	5.6	26
144	Autoimmunthyreopathien in der Schwangerschaft. <i>Geburtshilfe Und Frauenheilkunde</i> , 2005 , 65, 744-750	2	
143	Diagnosis of Medullary Thyroid Cancer 2005 , 297-309		1
142	Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2004 , 112, 52-8	2.3	97
141	Severe form of thyroid hormone resistance in a patient with homozygous/hemizygous mutation of T3 receptor gene. <i>European Journal of Endocrinology</i> , 2004 , 150, 819-23	6.5	23
140	Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). <i>Clinical Chemistry and Laboratory Medicine</i> , 2004 , 42, 90-5	5.9	43
139	Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. <i>Surgery</i> , 2004 , 136, 1083-7	3.6	19
138	Early malignant progression of hereditary medullary thyroid cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 1517-25	59.2	408
137	Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. <i>International Journal of Cancer</i> , 2001 , 95, 62-6	7.5	106
136	Guidelines for diagnosis and therapy of MEN type 1 and type 2. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5658-71	5.6	1466
135	Hyper- und Hypoparathyreoidismus 2001 , 111-136		
134	Diagnosis of Medullary Thyroid Cancer 2001 , 239-249		1
133	Asymptomatic primary hyperparathyroidism--need to treat?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2000 , 108, 247-8	2.3	0
132	Sporadisches und hereditäres medulläres Schilddrüsenkarzinom [Klinik und Diagnostik]. <i>Langenbecks Archiv Für Chirurgie Supplement</i> , 2000 , 344-349		
131	Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. <i>Oncogene</i> , 1999 , 18, 1369-73	9.2	117
130	Bisphosphonate. <i>Der Gynakologe</i> , 1999 , 32, 902-909	0.1	

129	Prophylactic thyroidectomy in MEN IIA: does the calcitonin level correlate with tumor spread?. <i>Langenbecks Archiv Fur Chirurgie</i> , 1998 , 383, 170-3		13
128	German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2. <i>Langenbecks Archives of Surgery</i> , 1998 , 383, 334-6	3.4	55
127	Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998 , 25, 424-30	8.8	83
126	Increased incidence of cardiovascular diseases in primary hyperparathyroidism--a cause for more aggressive treatment?. <i>European Journal of Clinical Investigation</i> , 1998 , 28, 277-8	4.6	12
125	A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 770-4	5.6	194
124	Routine calcitonin determination in thyroid nodules--an effective approach?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998 , 106, 289-91	2.3	12
123	Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998 , 106, 353-9	2.3	36
122	Einfluß der primären chirurgischen Therapie auf den Verlauf des C-Zell-Karzinoms der Schilddrüse 1998 , 1041-1043		
121	Results and follow-up in eleven MEN 2A gene carriers after prophylactic thyroidectomy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1997 , 105 Suppl 4, 76-8	2.3	9
120	Biochemical parameters in diagnosis and follow-up of patients with multiple endocrine neoplasia type 2. <i>Acta Chirurgica Austriaca</i> , 1997 , 29, 9-11		1
119	Chemotherapie bei Schilddrüsenkarzinomen: Indikation und Ergebnisse. <i>Onkologe</i> , 1997 , 3, 55-58	0.1	10
118	Medulläres Schilddrüsenkarzinom 1997 , 914-930		
117	Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2--relevance of specific mutations in the RET proto-oncogene. <i>European Journal of Endocrinology</i> , 1996 , 135, 222-5	6.5	34
116	Application of genetic screening in families with hereditary medullary thyroid carcinoma. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996 , 104 Suppl 4, 108-10	2.3	8
115	Norepinephrine induced calcitonin secretion in rat medullary thyroid carcinoma 6-23 cells: interaction between intracellular calcium and cAMP. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996 , 104, 43-9	2.3	17
114	Glucocorticoids decrease the production of parathyroid hormone-related protein in vitro but not in vivo in the Walker carcinosarcoma 256 rat model. <i>Bone</i> , 1996 , 18, 315-9	4.7	12
113	Mutations in the RET Proto-Oncogene in German Families with Multiple Endocrine Neoplasia Type 2 1996 , 119-121		
112	Köberling-Dunnigan syndrome: a rare cause of generalized muscular hypertrophy. <i>Muscle and Nerve</i> , 1996 , 19, 843-7	3.4	12

111	Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 1780-3	5.6	102
110	Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. <i>Cancer Research</i> , 1996 , 56, 2167-70	10.1	101
109	The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. <i>JAMA - Journal of the American Medical Association</i> , 1996 , 276, 1575-9	27.4	233
108	Effects of passive immunization against parathyroid hormone-related protein: PTHrP is the responsible factor in mediating hypercalcemia in the Walker carcinosarcoma 256 rat model. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 7-16	6.3	8
107	Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2. <i>Journal of Molecular Medicine</i> , 1995 , 73, 229-33	5.5	8
106	External radiotherapy of pituitary adenomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 33, 307-14	4	129
105	Evaluation of somatostatin as a plasma tumor marker in medullary thyroid carcinoma. <i>Thyroid</i> , 1995 , 5, 287-91	6.2	6
104	Extracellular calcium sensitivity and voltage-dependent calcium channels in C cells. <i>Endocrine Reviews</i> , 1995 , 16, 752-64	27.2	10
103	Adenosine A1-receptors inhibit cAMP and Ca ²⁺ mediated calcitonin secretion in C-cells. <i>Hormone and Metabolic Research</i> , 1995 , 27, 408-14	3.1	3
102	Clinical significance of antibodies against calcitonin. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1995 , 103, 345-51	2.3	29
101	Parathyroid hormone-related peptide and 8701-BC breast cancer cell growth and invasion in vitro: evidence for growth-inhibiting and invasion-promoting effects. <i>Molecular and Cellular Endocrinology</i> , 1995 , 111, 225-32	4.4	55
100	Crucial role of c-myc in 1,25(OH) ₂ D ₃ control of C-cell-carcinoma proliferation. <i>Biochemical and Biophysical Research Communications</i> , 1995 , 213, 922-7	3.4	2
99	Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. <i>Surgery</i> , 1995 , 118, 1099-103; discussion 1103-4	3.6	42
98	Microsurgical neck dissection for metastasizing medullary thyroid carcinoma. <i>European Journal of Surgical Oncology</i> , 1995 , 21, 195-7	3.6	15
97	Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. <i>Clinical Endocrinology</i> , 1995 , 43, 123-7	3.4	143
96	Response to methimazole in Graves disease. The European Multicenter Study Group. <i>Clinical Endocrinology</i> , 1995 , 43, 257-63	3.4	53
95	Somatostatin receptor imaging in persistent medullary thyroid carcinoma. <i>Clinical Endocrinology</i> , 1995 , 42, 31-7	3.4	59
94	Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. <i>Journal of Internal Medicine</i> , 1995 , 238, 343-6	10.8	218

93	Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. <i>Journal of Internal Medicine</i> , 1995 , 238, 369-73	10.8	100
92	Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. <i>Genes Chromosomes and Cancer</i> , 1995 , 12, 209-12	5	135
91	Spezifische ret proto-onkogen Mutationen bei verschiedenen hereditären Formen des C-Zell-Karzinoms 1995 , 303-306		
90	Multiple Endocrine Neoplasia Type 2: Clinical Features and Screening. <i>Endocrinology and Metabolism Clinics of North America</i> , 1994 , 23, 137-156	5.5	77
89	Increased prevalence of colonic adenomas in patients with acromegaly. <i>European Journal of Endocrinology</i> , 1994 , 131, 235-7	6.5	57
88	Surgical Therapy and Prognostic Factors in Medullary Thyroid Carcinoma (MTC). Current Evaluation of the German MTC Study Group. <i>Oncology Research and Treatment</i> , 1994 , 17, 594-599	2.8	1
87	Multiple endocrine neoplasia type 2. Clinical features and screening. <i>Endocrinology and Metabolism Clinics of North America</i> , 1994 , 23, 137-56	5.5	13
86	Epidemiological aspects of hypercalcemia of malignancy. <i>Recent Results in Cancer Research</i> , 1994 , 137, 99-106	1.5	8
85	Drug therapy of hypercalcemia due to malignancy. <i>Recent Results in Cancer Research</i> , 1994 , 137, 138-60	1.5	5
84	Formation of neutralizing antibodies after treatment with human calcitonin. <i>American Journal of Medicine</i> , 1993 , 95, 439-42	2.4	16
83	Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955. <i>Hormone and Metabolic Research</i> , 1993 , 25, 40-4	3.1	17
82	Diminished calcitonin secretion after ovariectomy without apparent reduction in calcitonin content in the rat. <i>Hormone and Metabolic Research</i> , 1993 , 25, 389-90	3.1	5
81	Long-term exposure to SMS 201-995 inhibits proliferation and calcitonin release in neoplastic C-cells. <i>Hormone and Metabolic Research</i> , 1993 , 25, 528-31	3.1	4
80	Cyclic AMP formation in rat bone and kidney cells is stimulated equally by parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1993 , 101, 150-5	2.3	14
79	Neutralizing antibodies against calcitonin. <i>Hormone and Metabolic Research</i> , 1993 , 25, 486-8	3.1	18
78	Regulation of calcitonin secretion in vitro. <i>Hormone and Metabolic Research</i> , 1993 , 25, 473-6	3.1	9
77	Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993 , 76, 801-3	5.6	44
76	Homologous desensitization of calcitonin receptors and calcitonin-dependent adenylate cyclase in T47D cells. <i>European Journal of Endocrinology</i> , 1993 , 128, 373-8	6.5	5

75	The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. <i>Nuclear Medicine Communications</i> , 1993 , 14, 439-45	1.6	15
74	Major role of dihydropyridine-sensitive Ca ²⁺ channels in Ca(2+)-induced calcitonin secretion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1993 , 264, E354-60	6	6
73	Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results. <i>Cancer</i> , 1993 , 72, 3685-93	6.4	53
72	Development and validation of an assay to measure bioactivity of human calcitonin in vitro using T47D cell membranes. <i>Analytical Biochemistry</i> , 1993 , 212, 91-7	3.1	4
71	Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. <i>The Clinical Investigator</i> , 1993 , 71, 7-12		109
70	Levels of parathyroid hormone-related protein in hypercalcemia of malignancy: comparison of midregional radioimmunoassay and two-site immunoradiometric assay. <i>The Clinical Investigator</i> , 1993 , 71, 31-6		9
69	In vitro-Bioassays für humanes Calcitonin. <i>Ersatz- Und Ergänzungsmethoden Zu Tierversuchen</i> , 1993 , 198-204		
68	Regulation of calcitonin gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 1233-7	6.3	26
67	In vitro secretion of calcitonin from a rat C cell line: effect of repetitive stimulation with the calcium channel agonist BAY K 8644. <i>Hormone and Metabolic Research</i> , 1992 , 24, 272-5	3.1	3
66	Determination of serum calcitonin by immunometric two-site assays in normal subjects and patients with medullary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 1992 , 30, 831-5	5.9	1
65	Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density. <i>Journal of Endocrinology</i> , 1992 , 134, 141-7	4.7	16
64	Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. <i>Thyroid</i> , 1992 , 2, 113-7	6.2	60
63	Chromogranin A as tumor marker in medullary thyroid carcinoma. <i>Thyroid</i> , 1992 , 2, 5-10	6.2	33
62	Clinical features of multiple endocrine neoplasia type 1 and type 2. <i>Hormone Research</i> , 1992 , 38 Suppl 2, 31-5		19
61	Somatostatin inhibits the norepinephrine-activated calcium channels in rMTC 6-23 cells: possible involvement of a pertussis toxin-sensitive G-protein. <i>European Journal of Endocrinology</i> , 1992 , 127, 378-84	6.5	6
60	Evaluation of sensitive PDN-21 (katacalcin) determination as tumor marker in medullary thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 1992 , 15, 93-8	5.2	10
59	Tumor necrosis factor alpha inhibits the stimulatory effect of the parathyroid hormone-related protein on cyclic AMP formation in osteoblast-like cells via protein kinase C+. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 182, 341-7	3.4	13
58	A new in vitro bioassay for human calcitonin: validation and comparison to the rat hypocalcemia bioassay. <i>Bone and Mineral</i> , 1992 , 17, 65-74		11

57	Inhibitory effect of somatostatin on cAMP accumulation and calcitonin secretion in C-cells: involvement of pertussis toxin-sensitive G-proteins. <i>Molecular and Cellular Endocrinology</i> , 1992 , 86, 213-9	4.4	10
56	Asymptomatischer primärer Hyperparathyreoidismus: pro Verlaufsbeobachtung. <i>Acta Chirurgica Austriaca</i> , 1992 , 24, 70-72		
55	Inhibition of Ca(2+)-induced calcitonin secretion by somatostatin: roles of voltage dependent Ca2+ channels and G-proteins. <i>Cellular Signalling</i> , 1992 , 4, 77-85	4.9	15
54	Circulating levels of midregional parathyroid hormone-related protein in hypercalcaemia of malignancy. <i>Clinical Endocrinology</i> , 1992 , 37, 290-7	3.4	34
53	Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statement. European Community Concerted Action: Medullary Thyroid Carcinoma. <i>European Journal of Clinical Investigation</i> , 1992 , 22, 755-60	4.6	28
52	The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. <i>Archives of Internal Medicine</i> , 1992 , 152, 1250-2		19
51	Measurement of free cytosolic calcium in single cells: method and application. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 1992 , 14, 327-32		1
50	Regulation of calcitonin secretion and calcitonin gene expression. <i>Recent Results in Cancer Research</i> , 1992 , 125, 1-18	1.5	3
49	Postsurgical follow-up and management. <i>Recent Results in Cancer Research</i> , 1992 , 125, 197-211	1.5	2
48	Screening for MEN 2 with biochemical and genetic markers. <i>Recent Results in Cancer Research</i> , 1992 , 125, 105-23	1.5	1
47	Tumorbedingte Hyperkalzämie. Therapie mit Bisphosphonaten. <i>Innovative Aspekte Der Klinischen Medizin</i> , 1992 , 93-97		
46	Effects of 17 beta-estradiol on calcitonin secretion and content in a human medullary thyroid carcinoma cell line. <i>Journal of Bone and Mineral Research</i> , 1991 , 6, 1191-5	6.3	6
45	Superior local tolerability of human versus salmon calcitonin preparations in young healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1991 , 41, 211-5	2.8	9
44	Papillary carcinoma in an ectopic thyroid. <i>Hormone Research</i> , 1991 , 35, 86-8		31
43	Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 1990 , 116, 21-3	4.9	82
42	In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin. <i>Journal of Bone and Mineral Research</i> , 1990 , 5, 387-91	6.3	23
41	Changing Concepts in the Management of Hereditary and Sporadic Medullary Thyroid Carcinoma. <i>Endocrinology and Metabolism Clinics of North America</i> , 1990 , 19, 613-635	5.5	40
40	Internalization of calcitonin receptors in primary rat kidney cell cultures. <i>European Journal of Endocrinology</i> , 1990 , 122, 255-62	6.5	5

39	A study of complaints and their relation to vertebral destruction in patients with osteoporosis. <i>Bone and Mineral</i> , 1990 , 8, 217-29		161
38	1,25-Dihydroxyvitamin D3 suppresses dexamethasone effects on calcitonin secretion. <i>Molecular and Cellular Endocrinology</i> , 1990 , 71, R13-8	4.4	8
37	New operative strategy in the treatment of metastasizing medullary carcinoma of the thyroid. <i>European Journal of Surgical Oncology</i> , 1990 , 16, 366-9	3.6	21
36	Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma. <i>Endocrinology and Metabolism Clinics of North America</i> , 1990 , 19, 613-35	5.5	7
35	The calcitonin receptor: characterization and processing. <i>Progress in Clinical and Biological Research</i> , 1990 , 332, 67-79		
34	Endocrine aspects of medullary thyroid carcinoma. <i>Recent Results in Cancer Research</i> , 1990 , 118, 64-9	1.5	1
33	Diagnostic Value of the Peptides from the Calcitonin Gene 1990 , 48-59		
32	Role of voltage-dependent calcium channels in secretion of calcitonin from human medullary thyroid carcinoma cells. <i>Klinische Wochenschrift</i> , 1989 , 67, 635-9		13
31	Reversible desensitization of calcitonin secretion by repetitive stimulation with calcium. <i>Molecular and Cellular Endocrinology</i> , 1989 , 63, 263-6	4.4	14
30	Rhythmic oscillations of cytosolic free calcium in rat C-cells. <i>Molecular and Cellular Endocrinology</i> , 1989 , 64, 267-70	4.4	19
29	Enhanced calcitonin secretion in the rat after parathyroidectomy and during chronic calcium deprivation. <i>European Journal of Clinical Investigation</i> , 1988 , 18, 284-9	4.6	8
28	Down-regulation of calcitonin receptors in T47D cells by internalization of calcitonin-receptor complexes. <i>Molecular and Cellular Endocrinology</i> , 1988 , 58, 9-15	4.4	25
27	Action of calcitonin gene-related peptide at the calcitonin receptor of the T47D cell line. <i>Hormone and Metabolic Research</i> , 1987 , 19, 563-4	3.1	11
26	Synaptophysin identified in metastases of neuroendocrine tumors by immunocytochemistry and immunoblotting. <i>American Journal of Clinical Pathology</i> , 1987 , 88, 560-9	1.9	36
25	Sensitive homologous radioimmunoassay for human parathyroid hormone to diagnose hypoparathyroid conditions. <i>Annals of Clinical Biochemistry</i> , 1987 , 24 (Pt 6), 608-13	2.2	7
24	Procollagen-III peptide serum levels in Paget's disease of the bone. <i>Klinische Wochenschrift</i> , 1987 , 65, 174-8		3
23	Neuron-specific enolase in medullary thyroid carcinoma: immunohistochemical demonstration, but no significance as serum tumor marker. <i>Journal of Cancer Research and Clinical Oncology</i> , 1987 , 113, 599-602	4.0	9
22	Importance of ultrasound examination for the follow-up of medullary thyroid carcinoma: comparison with other localization methods. <i>Henry Ford Hospital Medical Journal</i> , 1987 , 35, 122-3		9

21	In vitro secretion of peptides of the calcitonin family: calcitonin, katacalcin, and calcitonin gene-related peptide. <i>Henry Ford Hospital Medical Journal</i> , 1987 , 35, 143-6		3
20	Tumormarker beim C-Zellkarzinom der Schilddrüse: Katakalin, Kalzitonin, Kalzitonin- gene-related-peptide und karzinoembryonales Antigen 1987 , 258-259		
19	Nebenschilddrüsencarcinom und medulläres Schilddrüsencarcinom 1987 , 83-92		1
18	Metastatic C-cell carcinoma: calcitonin and CEA production in monolayer culture. <i>Journal of Cancer Research and Clinical Oncology</i> , 1986 , 111, 284-8	4.9	1
17	Inherited thyroxine-binding globulin excess. Study in a kindred. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1986 , 88, 237-41	2.3	
16	Pheochromocytoma in multiple endocrine neoplasia. <i>Cardiology</i> , 1985 , 72 Suppl 1, 147-9	1.6	3
15	120. Therapeutische Aspekte und Möglichkeiten beim Rezidiv des C-Zell-Carcinoms der Schilddrüse. <i>Konstr Masch Appar Geraetebau</i> , 1985 , 366, 590-590		
14	Secretion of calcitonin and carcinoembryonic antigen in long-term organ culture of human medullary thyroid carcinoma: biochemical and immunocytochemical studies. <i>Klinische Wochenschrift</i> , 1985 , 63, 205-10		4
13	Calcitonin in human pathophysiology. <i>Hormone Research</i> , 1984 , 20, 65-73		19
12	Reversible diminished calcitonin secretion in the rat during chronic hypercalcemia. <i>Endocrinology</i> , 1984 , 115, 2362-7	4.8	30
11	Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B). <i>European Journal of Pediatrics</i> , 1984 , 143, 112-6	4.1	8
10	Different effects of hypercalcemic state induced by Walker tumor (HWCS 256) and 1,25 (OH)D3 intoxication on rat thyroid C cells. An ultrastructural, immunocytochemical, and biochemical study. <i>Histochemistry</i> , 1984 , 80, 503-8		6
9	Postersession I. <i>Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin</i> , 1984 , 1207-1247		
8	Acute effect of 1,25-dihydroxy-vitamin D3 on calcitonin secretion in rats. <i>Hormone and Metabolic Research</i> , 1983 , 15, 208-9	3.1	10
7	Homologous radioimmunoassay for human parathyrin (residues 53-84).. <i>Clinical Chemistry</i> , 1982 , 28, 1749-51	4.1	17
6	Radioimmunoassay for human parathyroid hormone for differentiation between patients with hypoparathyroidism, hyperparathyroidism and normals. <i>Hormone and Metabolic Research</i> , 1979 , 11, 375-8	3.1	11
5	Hypercalcitoninaemia in patients with pheochromocytoma. <i>Klinische Wochenschrift</i> , 1978 , 56, 697-701		20
4	Dynamics of osteoclasia in rats with Walker tumor. <i>Calcified Tissue Research</i> , 1977 , 22 Suppl, 368-70		2

- 3 The hypercalcaemic syndrome in rats bearing the Walker carcinosarcoma 256. *European Journal of Endocrinology*, **1975**, 78, 613-24 6.5 35
- 2 Multiple Endocrine Neoplasia Type 21-8
- 1 Multiple Endocrine Neoplasia Type 2 2